"epidermal growth factor receptors" trang 10 - tải miễn phí từ tailieunhanh
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
9    50    1
Effectiveness of the AJCC 8th edition staging system for selecting patients with T1–2N1 breast cancer for post-mastectomy radiotherapy: A joint analysis of 1986 patients from two institutions

Effectiveness of the AJCC 8th edition staging system for selecting patients with T1–2N1 breast cancer for post-mastectomy radiotherapy: A joint analysis of 1986 patients from two institutions
11    48    1
Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition

Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition
12    28    1
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR

Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR
7    39    1
Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors

Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors
19    24    1
Mitogen-activated protein kinase activator with WD40 repeats (MAWD) and MAWDbinding protein induce cell differentiation in gastric cancer

Mitogen-activated protein kinase activator with WD40 repeats (MAWD) and MAWDbinding protein induce cell differentiation in gastric cancer
14    40    1
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: A retrospective study in 107 patients

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: A retrospective study in 107 patients
7    31    1
Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis

Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis
15    28    1
The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
9    22    1
Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization

Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization
12    22    1
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
13    46    1
Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
8    34    1
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients

Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients
12    34    1
Poor prognosis of single hormone receptorpositive breast cancer: Similar outcome as triple-negative breast cancer

Poor prognosis of single hormone receptorpositive breast cancer: Similar outcome as triple-negative breast cancer
9    61    1
The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer

The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer
7    52    1
Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: The support trial

Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: The support trial
7    62    1
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: An effect mediated by EGFR inhibition, p53 acetylation and oxidative stress

Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: An effect mediated by EGFR inhibition, p53 acetylation and oxidative stress
14    38    1
The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
12    47    1
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
8    41    1
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
10    50    1